{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:17:19Z","timestamp":1761844639579},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:p>Because of the well-known heterogeneity of melanomas, prognosis of the disease is often difficult to assess even for lesions classified in similar stages. The aim of this study was to assess the usefulness of COX-2 as a melanoma prognostic marker and to establish an optimum algorithm for analysis of COX-2 expression levels in lesions of interest. Expression of COX-2 was detected immunohistochemically in standard sections of formalin-fixed paraffin-embedded tissue samples of 85 primary melanomas, 36 lymph node metastases, and five skin metastases including 39 cases of paired primary and metastatic lesions obtained from the same patient. Enhanced expression of COX-2 in primary melanomas is an indicator of poorer prognosis. A significant correlation was found between high expression of COX-2 in primary lesions and shorter survival. The enhancement of COX-2 expression is also positively correlated with other prognostic factors such as tumor thickness and infiltration level, ulceration, high mitotic index, more invasive histologic type, vertical growth phase, and lymph node metastasis. On the whole, the results suggest that intratumoral expression of COX-2 is a strong negative prognostic marker for patients with melanoma. Moreover, our work shows that a simple and objective immunohistochemical scoring algorithm involving the determination of only a percentage fraction of positively stained cells is sufficient to obtain the prognostic information.<\/jats:p>","DOI":"10.1097\/cmr.0000000000000282","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T18:22:27Z","timestamp":1467915747000},"page":"448-456","source":"Crossref","is-referenced-by-count":15,"title":["Intratumoral expression of cyclooxygenase-2 (COX-2) is a negative prognostic marker for patients with cutaneous melanoma"],"prefix":"10.1097","volume":"26","author":[{"given":"\u0141ukasz","family":"Ku\u017abicki","sequence":"first","affiliation":[{"name":"Department of Medical Biology, Faculty of Biology and Environment Protection, Nicolaus Copernicus University, Toru\u0144"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dariusz","family":"Lange","sequence":"additional","affiliation":[{"name":"Department of Tumor Pathology, Oncology Center \u2013 Maria Sk\u0142odowska-Curie Institute, Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Stanek-Widera","sequence":"additional","affiliation":[{"name":"Department of Tumor Pathology, Oncology Center \u2013 Maria Sk\u0142odowska-Curie Institute, Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara W.","family":"Chwirot","sequence":"additional","affiliation":[{"name":"Department of Medical Biology, Faculty of Biology and Environment Protection, Nicolaus Copernicus University, Toru\u0144"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00000658-198808000-00004","article-title":"Lethal \u2018thin\u2019 malignant melanoma. Identifying patients at risk","volume":"208","author":"Slingluff","year":"1988","journal-title":"Ann Surg"},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/01.sla.0000090446.63327.40","article-title":"Thin melanomas: predictive lethal characteristics from a 30-year clinical experience","volume":"238","author":"Kalady","year":"2003","journal-title":"Ann Surg"},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1245\/ASO.2006.05.011","article-title":"Predictors of regional nodal disease in patients with thin melanomas","volume":"13","author":"Karakousis","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1245\/s10434-012-2826-0","article-title":"Sentinel node biopsy in thin and thick melanoma","volume":"20","author":"Mozzillo","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1590\/S0100-879X2003000300009","article-title":"Vertical growth phase and positive sentinel node in thin melanoma","volume":"36","author":"Filho","year":"2003","journal-title":"Braz J Med Biol Res"},{"key":"R7-20230902","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00259-011-2009-4","article-title":"Prognostic value of sentinel lymph node biopsy in 121 low-risk melanomas (tumour thickness<1.00\u2009mm) on the basis of a long-term follow-up","volume":"39","author":"Hinz","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaad.2015.09.014","article-title":"A retrospective, multicenter analysis of the predictive value of mitotic rate for sentinel lymph node (SLN) positivity in thin melanomas","volume":"74","author":"Wat","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3892\/or.2014.3531","article-title":"Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: a 5-year survival analysis","volume":"32","author":"Donizy","year":"2014","journal-title":"Oncol Rep"},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1046\/j.1365-2559.1996.d01-464.x","article-title":"The evaluation of diagnostic and prognostic criteria and the terminology of thin cutaneous malignant melanoma by the CRC melanoma pathology panel","volume":"28","author":"Cook","year":"1996","journal-title":"Histopathology"},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/path.1061","article-title":"Inter-observer variation in the histopathological diagnosis of clinically suspicious pigmented skin lesions","volume":"196","author":"Brochez","year":"2002","journal-title":"J Pathol"},{"key":"R12-20230902","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1097\/00000478-200312000-00011","article-title":"Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas","volume":"27","author":"Scolyer","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"R13-20230902","first-page":"449","article-title":"Prognostic factors for melanoma progression and metastasis: from hematoxylin\u2013eosin to genetics","volume":"53","author":"Fernandez-Flores","year":"2012","journal-title":"Rom J Morphol Embryol"},{"key":"R14-20230902","first-page":"383","article-title":"Evaluating biomarkers in melanoma","volume":"4","author":"Karagiannis","year":"2015","journal-title":"Front Oncol"},{"key":"R15-20230902","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00428-013-1526-x","article-title":"Tissue prognostic biomarkers in primary cutaneous melanoma","volume":"464","author":"Mandal\u00e0","year":"2014","journal-title":"Virchows Arch"},{"key":"R16-20230902","first-page":"13","article-title":"Diagnostic and prognostic biomarkers in melanoma","volume":"7","author":"Weinstein","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"R17-20230902","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/CMR.0b013e3280dec6ac","article-title":"Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours","volume":"17","author":"Chwirot","year":"2007","journal-title":"Melanoma Res"},{"key":"R18-20230902","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/CMR.0b013e32834defec","article-title":"The value of cyclooxygenase-2 expression in differentiating between early melanomas and histopathologically difficult types of benign human skin lesions","volume":"22","author":"Ku\u017abicki","year":"2012","journal-title":"Melanoma Res"},{"key":"R19-20230902","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/01.cmr.0000194430.77643.a0","article-title":"Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression","volume":"16","author":"Ku\u017abicki","year":"2006","journal-title":"Melanoma Res"},{"key":"R20-20230902","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/CMR.0b013e32831d7f52","article-title":"COX-2 expression in malignant melanoma: a novel prognostic marker?","volume":"19","author":"Becker","year":"2009","journal-title":"Melanoma Res"},{"key":"R21-20230902","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/CMR.0b013e32835e7734","article-title":"Expression of thymidine phosphorylase and cyclooxygenase-2 in melanoma","volume":"23","author":"Minisini","year":"2013","journal-title":"Melanoma Res"},{"key":"R22-20230902","first-page":"848645","article-title":"Cyclooxygenase 2 (COX2) and peroxisome proliferator-activated receptor gamma (PPARG) are stage-dependent prognostic markers of malignant melanoma","volume":"2009","author":"Meyer","year":"2009","journal-title":"PPAR Res"},{"key":"R23-20230902","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00262-008-0631-1","article-title":"Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma","volume":"58","author":"Johansson","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"R24-20230902","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1600-0560.2007.00939.x","article-title":"Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression","volume":"35","author":"Lee","year":"2008","journal-title":"J Cutan Pathol"},{"key":"R25-20230902","doi-asserted-by":"crossref","first-page":"647684","DOI":"10.1155\/2012\/647684","article-title":"Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors","volume":"2012","author":"Tas","year":"2012","journal-title":"J Oncol"},{"key":"R26-20230902","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/01.cmr.0000205020.17774.ae","article-title":"Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor","volume":"16","author":"Lejeune","year":"2006","journal-title":"Melanoma Res"},{"key":"R27-20230902","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1080\/07357900601063790","article-title":"Clinical activity of celecoxib in metastatic malignant melanoma","volume":"24","author":"Wilson","year":"2006","journal-title":"Cancer Invest"},{"key":"R28-20230902","first-page":"3137","article-title":"High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer","volume":"33","author":"Elzagheid","year":"2013","journal-title":"Anticancer Res"},{"key":"R29-20230902","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1186\/1471-2407-14-952","article-title":"Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients","volume":"14","author":"Sicking","year":"2014","journal-title":"BMC Cancer"},{"key":"R30-20230902","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12957-014-0426-0","article-title":"Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy","volume":"13","author":"Shimizu","year":"2015","journal-title":"World J Surg Oncol"},{"key":"R31-20230902","article-title":"Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma","author":"Hang","year":"2016","journal-title":"Oncotarget"},{"key":"R32-20230902","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1007\/s11605-011-1814-1","article-title":"Cyclooxygenase isoenzyme-2 and vascular endothelial growth factor are associated with poor prognosis in esophageal adenocarcinoma","volume":"16","author":"Prins","year":"2012","journal-title":"J Gastrointest Surg"},{"key":"R33-20230902","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4132\/KoreanJPathol.2012.46.3.237","article-title":"Cyclooxygenase-2 expression and its prognostic significance in clear cell renal cell carcinoma","volume":"46","author":"Lee","year":"2012","journal-title":"Korean J Pathol"},{"key":"R34-20230902","first-page":"21","article-title":"Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in ovarian cancer","volume":"15","author":"Fujimoto","year":"2006","journal-title":"Oncol Rep"},{"key":"R35-20230902","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/ijc.21749","article-title":"Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence","volume":"119","author":"Cohen","year":"2006","journal-title":"Int J Cancer"},{"key":"R36-20230902","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1006\/jsre.2002.6532","article-title":"Role of cyclooxygenase-2 in breast cancer","volume":"108","author":"Singh","year":"2002","journal-title":"J Surg Res"},{"key":"R37-20230902","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2174\/1389450115666140127102915","article-title":"COX-2 signaling and cancer: new players in old arena","volume":"15","author":"Misra","year":"2014","journal-title":"Curr Drug Targets"},{"key":"R38-20230902","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12935-015-0260-7","article-title":"Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity","volume":"15","author":"Liu","year":"2015","journal-title":"Cancer Cell Int"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008390-201610000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T03:19:12Z","timestamp":1693624752000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008390-201610000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000282","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}